Leupin
Pharma
ArgenX
Belgium
Biography
Leupin was assigned to the lymphoma team, some years later to the myeloma team, Celgene’s prime indication, where he was instrumental in leading the European teams and in bridging with the US teams. Nicolas was Global Clinical Lead for several compounds up to phase III, where among other activities he was responsible for the summary of efficacy of registration dossiers that lead to successful European and American registrations. Nicolas Leupin holds an MBA with a focus on negotiation and conflict management, participated in various postgraduate courses, including the IMD in Lausanne. He keeps an academic activity and is still lecturer at the University of Bern.
Research Interest
Pharma
